Virilon (ENDOCRINE THERAPY)
Virilon (ENDOCRINE THERAPY) Uses, Dosage, Side Effects, Food Interaction and all others data.
A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Virilon (ENDOCRINE THERAPY) is a schedule III drug in the US.
Testosterone is a steroid hormone from the androgen group. Testosterone is primarily secreted from the testes of males. In females, it is produced in the ovaries, adrenal glands and by conversion of adrostenedione in the periphery. It is the principal male sex hormone and an anabolic steroid. In both males and females, it plays key roles in health and well-being. Examples include enhanced libido, energy, immune function, and protection against osteoporosis. On average, the adult male body produces about twenty times the amount of testosterone than an adult female's body does.
| Trade Name | Virilon (ENDOCRINE THERAPY) |
| Availability | Prescription only |
| Generic | Methyltestosterone |
| Methyltestosterone Other Names | 17-methyltestosterone, Methyltestosterone, Methyltestosteronum, Metiltestosterona |
| Related Drugs | estradiol, tamoxifen, Premarin, testosterone, megestrol, AndroGel, Xyosted, Depo-Testosterone, chorionic gonadotropin (hcg), Pregnyl |
| Type | |
| Formula | C20H30O2 |
| Weight | Average: 302.451 Monoisotopic: 302.224580204 |
| Protein binding | 40% of testosterone in plasma is bound to sex hormone-binding globulin and 2% remains unbound and the rest is bound to albumin and other proteins. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | USA |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Virilon (ENDOCRINE THERAPY) is a synthetic anabolic steroid used for the replacement therapy in conditions associated with testosterone deficiencies in males, such as hypogonadism, and treatment of advancing inoperable metastatic breast cancer in females.
Virilon (ENDOCRINE THERAPY) is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause.
Virilon (ENDOCRINE THERAPY) is also used to associated treatment for these conditions: Hypergonadotropic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Metastatic Breast Cancer, Puberty, Delayed, Testosterone Deficiency
How Virilon (ENDOCRINE THERAPY) works
The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
Toxicity
Side effects include amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation.
Food Interaction
No interactions found.Virilon (ENDOCRINE THERAPY) Cholesterol interaction
[Major] Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.
These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.
Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.
Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.
Virilon (ENDOCRINE THERAPY) Drug Interaction
Moderate: dexamethasone, dexamethasoneUnknown: aspirin, aspirin, ubiquinone, ubiquinone, dextran, low molecular weight, dextran, low molecular weight, ginkgo, ginkgo, acetaminophen, acetaminophen, topiramate, topiramate, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol
Virilon (ENDOCRINE THERAPY) Disease Interaction
Major: carcinoma (male), fluid retention, hypercalcemia in breast cancer, hyperlipoproteinemia, liver disease, polycythemia, suppression of clotting factorsModerate: diabetes, hypercalcemiaMinor: thyroid function tests
Elimination Route
The methyl group aids to increase oral bioavailability.
Half Life
6-8 hours
Elimination Route
90% urine / 10% feces
Innovators Monograph
You find simplified version here Virilon (ENDOCRINE THERAPY)
